Eli Lilly struck major collaborations in Asia, licensing ABL Bio’s Grabody bispecific platform in a deal valued at up to $2.6 billion and signing a $1.2 billion research pact with SanegeneBio to harness its LEAD RNAi delivery technology for metabolic targets. Lilly will leverage Grabody to expand CNS and oncology bispecifics and will advance optimized LEAD RNAi molecules into IND‑enabling development. The twin agreements represent a strategic push into engineered bispecifics and tissue‑targeted RNAi, reflecting large pharma’s continued appetite to buy or partner platform capabilities across Asia.